1. Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases.
- Author
-
Vilarrasa E, Nicolau J, de la Cueva P, Goday A, Gallardo F, Martorell A, and Carrascosa JM
- Subjects
- Humans, Hypoglycemic Agents pharmacology, Hypoglycemic Agents therapeutic use, Liraglutide therapeutic use, Obesity complications, Obesity drug therapy, Diabetes Mellitus, Type 2, Skin Diseases drug therapy, Skin Diseases etiology
- Abstract
Psoriasis and hidradenitis suppurativa are often associated with obesity. Because chronic low-grade inflammation underlies these 2 diseases, they can progress to more severe forms in patients with obesity if weight-reduction measures are not taken. This review covers pharmacologic alternatives for treating obesity, with emphasis on the benefits associated with the novel use of glucagon-like peptide-1 (GLP-1) agonists that act on satiety receptors. These drugs have led to greater weight loss in clinical trials and real-world settings than orlistat, which until recently was the only drug approved for treating obesity in the European Union. Although experience with GLP-1 agonists in patients with obesity and inflammatory skin diseases is currently scarce, the promising results reported suggest they may offer a useful tool for managing obesity., (Copyright © 2023 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF